I think this thesis has been hashed few times. And I absolutely agree. Happy patients are big favor and providers consider them recurring revenues and won’t take risk alienating them. However label is important to really cement this differentiation. My concern is with only 50% of trial patients showing 24w duration, is it enough to convince the FDA ?
Market Data 
Markets 
AI
